- Market Capitalization, $K 80,555
- Shares Outstanding, K 40,480
- Annual Sales, $ 0 K
- Annual Income, $ -24,960 K
- 60-Month Beta 2.45
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 4.56
|Period||Period Low||Period High||Performance|
| || |
+0.1300 (+6.99%)since 07/02/20
| || |
+0.4100 (+25.95%)since 05/05/20
| || |
+1.0600 (+113.98%)since 08/05/19
and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended . All dollar amounts are expressed in Canadian...
and , /PRNewswire/ Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on , at to discuss a corporate update and financial results for...
, /PRNewswire/ -- – Researchers at the Cancer Centerhave found a potential new combination therapy for breast cancer that would integrate the body's immune system with targeted treatment for a protein...
, /PRNewswire/ -- – A recent study from the National Comprehensive Cancer Center (NCCN) delivered a shocking indictment of the oncology field as a whole, stating that of women diagnosed with triple-negative...
, /PRNewswire/ -- – In a major step forward, engineers from have designed nanoparticles that stimulate the immune system, helping it to attack tumors. This could contribute significantly to other...
, /PRNewswire/ -- The triple negative breast cancer (TNBC) treatment market to grow at stellar CAGR through 2026. A from Cole Market Research has stated that the ongoing advancements in cancer research...
and , /PRNewswire/ --
, /PRNewswire/ -- Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT...
and , /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the first patient has been dosed in the Company's phase 2 study of pelareorep-based combination therapies in...
and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into...